FDA Accepts BLA for Datopotamab Deruxtecan for Pretreated HR+/HER2– Metastatic Breast Cancer

The FDA has accepted a biologics license application for datopotamab deruxtecan in HR-positive, HER2-negative metastatic breast cancer.

Related Keywords

Japan ,Canada ,United States ,China ,Susan Galbraith ,Daiichi Sankyo ,Ken Takeshita ,European Union ,Astrazeneca ,Prescription Drug User Fee ,